BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stockley RA, Edgar RG, Starkey S, Turner AM. Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respir Res 2018;19:137. [PMID: 30029692 DOI: 10.1186/s12931-018-0844-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chorostowska-Wynimko J, Wencker M, Horváth I. The importance of effective registries in pulmonary diseases and how to optimize their output. Chron Respir Dis 2019;16:1479973119881777. [PMID: 31645111 DOI: 10.1177/1479973119881777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
3 Herth FJF, Sandhaus RA, Turner AM, Sucena M, Welte T, Greulich T. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. Int J Chron Obstruct Pulmon Dis 2021;16:2983-96. [PMID: 34754184 DOI: 10.2147/COPD.S325211] [Reference Citation Analysis]
4 Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Sanderman R, Schultz K, Kocks J, van der Molen T. Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice. BMJ Open 2019;9:e025776. [PMID: 31256021 DOI: 10.1136/bmjopen-2018-025776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Campos MA, Geraghty P, Holt G, Mendes E, Newby PR, Ma S, Luna-Diaz LV, Turino GM, Stockley RA. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. Am J Respir Crit Care Med 2019;200:318-26. [PMID: 30965011 DOI: 10.1164/rccm.201901-0010OC] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
6 Miravitlles M, Herepath M, Priyendu A, Sharma S, Vilchez T, Vit O, Haensel M, Lepage V, Gens H, Greulich T. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. Eur Respir Rev 2022;31:210262. [PMID: 35321931 DOI: 10.1183/16000617.0262-2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pye A, Khan S, Whitehouse T, Turner AM. Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency. Expert Review of Precision Medicine and Drug Development 2021;6:65-78. [DOI: 10.1080/23808993.2021.1862648] [Reference Citation Analysis]
8 Crossley D, Stockley J, Bolton CE, Hopkinson NS, Mahadeva R, Steiner M, Wilkinson T, Hurst JR, Gooptu B, Stockley RA. Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. BMJ Open 2020;10:e036045. [PMID: 32606060 DOI: 10.1136/bmjopen-2019-036045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]